119 related articles for article (PubMed ID: 1933775)
1. Thyroid dysfunction associated with immunotherapy for patients with cancer.
Schwartzentruber DJ; White DE; Zweig MH; Weintraub BD; Rosenberg SA
Cancer; 1991 Dec; 68(11):2384-90. PubMed ID: 1933775
[TBL] [Abstract][Full Text] [Related]
2. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies.
Vialettes B; Guillerand MA; Viens P; Stoppa AM; Baume D; Sauvan R; Pasquier J; San Marco M; Olive D; Maraninchi D
Acta Endocrinol (Copenh); 1993 Jul; 129(1):31-8. PubMed ID: 8351956
[TBL] [Abstract][Full Text] [Related]
3. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
[TBL] [Abstract][Full Text] [Related]
4. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone.
Krouse RS; Royal RE; Heywood G; Weintraub BD; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
J Immunother Emphasis Tumor Immunol; 1995 Nov; 18(4):272-8. PubMed ID: 8680655
[TBL] [Abstract][Full Text] [Related]
5. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.
Weijl NI; Van der Harst D; Brand A; Kooy Y; Van Luxemburg S; Schroder J; Lentjes E; Van Rood JJ; Cleton FJ; Osanto S
J Clin Oncol; 1993 Jul; 11(7):1376-83. PubMed ID: 8315436
[TBL] [Abstract][Full Text] [Related]
6. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.
Franzke A; Peest D; Probst-Kepper M; Buer J; Kirchner GI; Brabant G; Kirchner H; Ganser A; Atzpodien J
J Clin Oncol; 1999 Feb; 17(2):529-33. PubMed ID: 10080596
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
[TBL] [Abstract][Full Text] [Related]
8. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells.
Kung AW; Lai CL; Wong KL; Tam CF
Q J Med; 1992 Jan; 82(297):33-42. PubMed ID: 1332102
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.
Daniels GH; Vladic A; Brinar V; Zavalishin I; Valente W; Oyuela P; Palmer J; Margolin DH; Hollenstein J
J Clin Endocrinol Metab; 2014 Jan; 99(1):80-9. PubMed ID: 24170099
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune thyroid disorders in SLE in Singapore.
Boey ML; Fong PH; Lee JS; Ng WY; Thai AC
Lupus; 1993 Feb; 2(1):51-4. PubMed ID: 8485560
[TBL] [Abstract][Full Text] [Related]
11. Can thyroid volume predict thyroid dysfunction in patients with systemic sclerosis? A prospective cross-sectional study from a tertiary care center in North West India.
Singh PK; Sharma SK; Sinha A; Dutta P
Clin Rheumatol; 2016 Mar; 35(3):765-9. PubMed ID: 26861031
[TBL] [Abstract][Full Text] [Related]
12. [Thyroid dysfunctions secondary to cancer immunotherapy].
Cugnet Anceau C; Abeillon J; Maillet D; Borson-Chazot F; Disse E
Bull Cancer; 2020 Feb; 107(2):262-271. PubMed ID: 31879018
[TBL] [Abstract][Full Text] [Related]
13. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy.
Deutsch M; Dourakis S; Manesis EK; Gioustozi A; Hess G; Horsch A; Hadziyannis S
Hepatology; 1997 Jul; 26(1):206-10. PubMed ID: 9214471
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus.
Celani MF; Bonati ME; Stucci N
Diabetes Res; 1994; 27(1):15-25. PubMed ID: 7648793
[TBL] [Abstract][Full Text] [Related]
15. Expert opinion on thyroid complications in immunotherapy.
Illouz F; Drui D; Caron P; Do Cao C
Ann Endocrinol (Paris); 2018 Oct; 79(5):555-561. PubMed ID: 30126627
[TBL] [Abstract][Full Text] [Related]
16. Thyroid function and circulating antithyroid antibodies in myasthenia gravis.
Kiessling WR; Pflughaupt KW; Ricker K; Haubitz I; Mertens HG
Neurology; 1981 Jun; 31(6):771-4. PubMed ID: 6787459
[TBL] [Abstract][Full Text] [Related]
17. Thyroid dysfunction induced by interferon therapy for the treatment of hepatitis type C. A report of 4 cases.
Yamakawa Y; Sata M; Nakano H; Ide T; Noguchi S; Tokeshi S; Tanikawa K
Kurume Med J; 1995; 42(4):313-9. PubMed ID: 8667604
[TBL] [Abstract][Full Text] [Related]
18. Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.
Reid I; Sharpe I; McDevitt J; Maxwell W; Emmons R; Tanner WA; Monson JR
Br J Cancer; 1991 Nov; 64(5):915-8. PubMed ID: 1931616
[TBL] [Abstract][Full Text] [Related]
19. [The prevalence of thyro-peroxidase antibodies and thyroid function in Turner's syndrome].
Wikiera B; Barg E; Konieczna A; Głab E; Noczyńska A
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):190-4. PubMed ID: 17020654
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
